An Expert Approach to Cardio-Renal Protection in CKD: Part Two

Published: 07 May 2024

  • Views:

    Views Icon 5146

  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

Chaired by Prof James Burton (University of Leicester, UK), this roundtable features expert insight from a world-renowned faculty, Prof David Wheeler (University College London, UK) and Dr Navdeep Tangri (University of Manitoba, CA).

 

Dr Tangri begins by providing an overview of the recent KDIGO guideline updates. Following this, the panel recap on the patient case that was presented in part one of this programme. The faculty discuss why the guidelines were updated and how the updates may impact the management strategy of the patient. They continue to provide practical advice for initiating cardiorenal protection therapy in non-diabetic CKD patients. 

 

Note, the live version of this session was CME accredited; this on-demand version is not.

 

Watch Part One Here
Download the KDIGO 2024 CKD Guidelines 
This programme is supported by an unrestricted educational grant from AstraZeneca.

Key Learning Objectives

  • Recall clinical evidence and guidelines for the management of CKD patients without diabetes
  • Describe current gaps and barriers in evidence-based management for CKD without diabetes
  • Apply evidence based-management strategies to a case study
  • Use expert-led guidance to develop an optimal management approach to CKD patients without diabetes

Target Audience

  • Cardiologists
  • Nephrologists
  • Heart Failure Specialists
  • Primary Care Physicians

More from this programme

Part 1

Review of Recommendations

1 session
Review of Recommendations Watch now

Part 2

Panel Discussion

2 sessions
Applying KDIGO Guidelines to a Patient Case Watch now
KDIGO Guidelines and Individualising Care Watch now

Part 3

Audience Q&A / Key Summary

6 sessions
Do you continue SGLT2 inhibitors in patients on dialysis? Watch now
Protein creatinine ratio (PCR) or albumin creatinine ratio (ACR)? Watch now
Do we start an SGLT2 inhibitor or RAASI therapy first? Watch now
Is one ACE inhibitor better than an other for patients with CKD? Watch now
Are SGLT2 inhibitors suitable for patients with high cardiovasular risk? Watch now
Key Summary Watch now

Faculty Biographies

James Burton

James Burton

Professor of Renal Medicine

Prof James Burton is Honorary Consultant Nephrologist and Professor of Renal Medicine and Associate Dean for Clinical Research at the University of Leicester, Leicester, UK. His principal research interests are the mechanisms underlying uraemic cardiovascular disease modification of cardiovascular risk in patients with end-stage renal disease and the identification and application of novel biomarkers.

In addition Prof Burton is involved in the development and running of clinical trials; he is Chief Investigator for the NIHR funded NightLife trial investigating the impact of nocturnal dialysis on patient outcomes as well as the Kidney Research UK funded CONFIRM study exploring the utility of a novel cardiac magnetic resonance imaging (MRI) techniques in haemodialysis patients. Prof Burton is the independent Chair of two multi-centre NIHR Trial Steering Committees and sits on a number of others.

He is the current Chair of the UK Kidney Association Clinical…

View full profile
Navdeep Tangri

Navdeep Tangri

Professor of Medicine in the Division of Nephrology

Dr Navdeep Tangri is a Professor of Medicine in the Division of Nephrology at University of Manitoba, Winnipeg, CA.

Dr Tangri's research programme is focused on the clinical management of patients with advanced chronic kidney disease. He developed the kidney failure risk equation (KFRE) to predict the need for dialysis in patients with chronic kidney disease.

View full profile
David Wheeler

David Wheeler

Professor of Kidney Medicine

David Wheeler is Professor of Kidney Medicine at University College London and Honorary Consultant Nephrologist at the Royal Free London NHS Foundation Trust.

Prof Wheeler is a clinician scientist interested in the complications of chronic kidney disease (CKD), specifically those that increase the burden of cardiovascular disease and/or accelerate progression of kidney failure. He has participated in the development and running of several large-scale clinical trials testing lipid-lowering regimens, calcimimetics, intravenous iron, sodium–glucose co-transporter 2 inhibitors and hypoxia-inducible factor stabilisers in patients with CKD.

Prof Wheeler has also been involved in the development of clinical practice guidelines for several organisations, most recently for Kidney Disease: Improving Global Outcomes (KDIGO). He served as KDIGO co-Chair between 2012 and 2019. His ongoing roles include serving as the National Specialty Lead for the…

View full profile

Comments

You must be to comment. If you are not registered, you can register here.